The effect of chemotherapy on lymphocyte subpopulations and cell-mediated cytotoxicity in patients with ovarian carcinoma.
Chemotherapy using adriamycin with cyclophosphamide, and cyclophosphamide with hexamethylmelamine or with alkeran causes no significant reduction in the total lymphocyte count, in the percentage subpopulations of T cells and B cells or in mononuclear cell cytotoxicity in patients with Stage II carcinoma of the ovary during their first course of chemotherapy.
D006585:Altretamine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008214:Lymphocytes / Q000187:drug effects*; D008558:Melphalan / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery; D013601:T-Lymphocytes / Q000187:drug effects; D013997:Time Factors
D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D006585:Altretamine